Time-averaged proteinuria (TAP) is thought to be the most reliable predictor of outcomes in IgA nephropathy (IgAN). New data suggest that corticosteroids reduce TAP and presumably improve outcomes in IgAN, but increase the risk of adverse effects. Whether TAP is a good surrogate end point for clinical trials remains unclear.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
International Society of Nephrology. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int. Suppl. 2, 139–274 (2012)
Reich, H. N., Troyanov, S., Scholey, J. W., Cattran, D. C. & Toronto Glomerulonephritis Registry. Remission of proteinuria improves prognosis in IgA nephropathy. J. Am. Soc. Nephrol. 18, 3177–3183 (2007).
Sarcina, C. et al. Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy. Clin. J. Am. Soc. Nephrol. http://dx.doi.org/10.2215/CJN.02300215, (2016).
Pozzi, C. et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J. Am. Soc. Nephrol. 15, 157–163 (2004).
Rauen, T. et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N. Engl. J. Med. 373, 2225–2236 (2015).
Inker, L. A. et al. Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am. J. Kidney Dis. http://dx.doi.org/10.1053/j.ajkd.2016.02.042, (2016).
Donadio, J. V. et al. A controlled trial of fish oil in IgA nephropathy. N. Engl. J. Med. 331, 1194–1199 (1994).
Nomura, A. et al. Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis. Am. J. Pathol. 151, 539–547 (1997).
US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01560052?term=NCT01560052&rank=1, (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Floege, J., Rauen, T. Immunosuppressant-induced reduction of proteinuria in IgAN. Nat Rev Nephrol 12, 380–382 (2016). https://doi.org/10.1038/nrneph.2016.84
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2016.84
